The rapid growth in the adoption of SomnoMed’s sleep apnea products in Europe as well as completion of its U.S. medical initiative are expected to help drive earnings growth in the 2015 financial year. EBITA is forecast at $2 million to $4 million on revenues of $32.5 million. Shares are expected to move higher today.
News: SomnoMed marks seventh year of growth, forecasts higher earnings
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
75.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $163.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 800 | 75.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 75.0¢ | 112368 | 2 |
View Market Depth
| Last trade - 09.45am 10/09/2025 (20 minute delay) ? |
| SOM (ASX) Chart |
Day chart unavailable